Mayne Pharma Group Limited announced it has appointed Mr. Shawn Patrick O'Brien as Chief Executive Officer (CEO) effective from 1 October 2022. This follows from the previously announced retirement of Mr. Scott Richards and a comprehensive search for a successor. Mr. O'Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises.

He is currently founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences.

Mr. O'Brien held multiple senior leadership roles at AstraZeneca. At AstraZeneca he was responsible for key brands such as FASLODEX®, SYMBICORT®, PULMICORT® and SEROQUEL® which all became billion-dollar brands.